Subacute Systemic Toxicity
#MEDISTRI
#MEDISTRI
Medistri continues to be at the forefront of regulatory requirements and quality proficiency.Subacute Systemic Toxicity is a critical aspect of health risk assessment that evaluates the effects of exposure to harmful substances over a period longer than immediate (acute) but shorter than chronic. This type of toxicity is essential in occupational safety, environmental health, and the development of medical and pharmaceutical products, as it helps to identify potential health risks that emerge from prolonged exposure.
Subacute Systemic Toxicity refers to the adverse effects that develop after repeated exposure to a substance over weeks, typically through ingestion, inhalation, or skin contact. Unlike acute toxicity, which presents with rapid onset symptoms, subacute toxicity involves a more gradual manifestation of effects. This makes it crucial for assessing longer-term health risks that might not be evident with immediate toxicity testing.
In the context of medical devices and pharmaceutical products, Subacute Systemic Toxicity testing plays a pivotal role in evaluating how materials and substances affect the body over extended exposure periods. By identifying potential risks early in the product development and validation stages, Medistri Laboratory can implement strategies to mitigate these risks, ensuring enhanced product safety and regulatory compliance.
Medistri Laboratory adheres to rigorous industry standards to conduct comprehensive subacute toxicity assessments.
We follow guidelines such as ISO 10993-11, which outlines procedures for evaluating the systemic toxicity of materials used in medical devices, ensuring they meet stringent safety criteria, that are resumed on the following points:
Study Design and Preparation
Exposure Routes
Test Subject Selection
Monitoring and Observation
Histopathological Examination
Data Analysis
Reporting and Documentation
Regulatory Compliance
Our testing protocols also include adherence to ASTM F750, which assists in assessing extractable components from medical plastics. This helps us understand and address potential systemic effects from substances that may leach out during extended exposure periods.
For pharmaceutical products, we ensure compliance with USP guidelines to verify their safety profiles before they are made available to healthcare providers and patients. This thorough approach helps to confirm that products are safe for use over longer periods, thereby maintaining high standards of quality and safety.
By incorporating these stringent standards into our procedures, we demonstrate our dedication to providing a service that not only complies with regulatory requirements but also adheres to the highest levels of safety and quality in the healthcare industry.
🎯 To learn more about Medistri’s Subacute Systemic Toxicity, visit on our website here or directly contact our team at contact@medistri.swiss.
- The Medistri Team
#Medistri
Follow us: Website, Blog, LinkedIn, Facebook, Twitter, Instagram and Medium.